{"filings":[{"id":1250077,"accession_number":"0001841387-26-000009","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-06-24T20:24:12+00:00","items":["5.07"],"status":"ready","headline":"Candel shareholders elect four Class II directors, ratify KPMG as auditor at June 23 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Edward J. Benz, Paul B. Manning, Maha Radhakrishnan, and Paul Peter Tak as Class II directors for three-year terms.","Director voting: Benz received 24.9M for, 6.8M withheld; Manning 31.6M for, 102k withheld; Radhakrishnan 31.0M for, 646k withheld; Tak 31.4M for, 279k withheld.","KPMG LLP ratified as independent auditor for FY 2026 with 53.5M for, 238k against, 88k abstain.","All proposals passed; no other matters were voted on at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1084476,"accession_number":"0001841387-26-000007","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-06-16T20:23:50+00:00","items":["5.02","9.01"],"status":"ready","headline":"Candel Therapeutics formalizes CFO employment agreement with $468,600 salary, 40% target bonus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Charles Schoch's new agreement sets base salary at $468,600 and target annual bonus at 40% of base.","Severance on termination without cause or for good reason: 9 months base salary plus target bonus.","Time-based equity awards fully accelerate if termination occurs within 1 month before or 12 months after change in control.","Agreement includes standard confidentiality, non-compete, and non-solicitation covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470996,"accession_number":"0001193125-26-226751","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-05-15T20:13:34+00:00","items":["7.01","9.01"],"status":"ready","headline":"Candel reports 39% improvement in prostate cancer-specific DFS with aglatimagene in phase 3 extended follow-up","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prostate cancer-specific DFS improved 39% vs placebo (HR 0.61, p=0.0031) at median 58-month follow-up.","Consistent favorable trends in TTBF, TTM, metastasis rate, and TTNT in ITT population.","In intermediate-risk subgroup (85% of patients), 90% reduction in time to metastasis (HR 0.1).","Company plans to submit BLA to FDA in Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":78041,"accession_number":"0001193125-26-222892","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-05-14T12:15:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Therapeutics Q1 2026 net loss $8.9M; BLA submission for CAN-2409 on track for Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.9M in Q1 2026 vs net income $7.4M in Q1 2025; R&D expense $9.8M.","Cash and equivalents $194.8M as of March 31, 2026, expected to fund operations into Q1 2028.","Plans to submit BLA for aglatimagene (CAN-2409) in localized prostate cancer in Q4 2026.","Extended follow-up from Phase 2a NSCLC trial shows 50% of patients survived >24 months; Phase 3 NSCLC trial to start June 2026.","Announced commercial partnership with EVERSANA and $100M royalty funding agreement with RTW for potential launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109730,"accession_number":"0001193125-26-103126","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel reports Q4 2025 net loss of $29.5M; cash $119.7M; plans BLA for aglatimagene in Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025: $29.5M vs $14.1M Q4 2024; full year net loss $38.2M vs $55.2M (2024).","Cash $119.7M at Dec 31, 2025; plus $93.5M net from Feb 2026 offering; runway into Q1 2028.","Entered $130M term loan with Trinity Capital; $50M drawn; $100M royalty deal with RTW contingent on FDA approval.","Plan to initiate pivotal phase 3 trial of aglatimagene in NSCLC in Q2 2026; BLA submission for prostate cancer in Q4 2026.","FDA cleared IND for linoserpaturev in recurrent high-grade glioma; mature OS data expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109729,"accession_number":"0001193125-26-062490","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Candel Therapeutics prices $100M public offering of 18.3M shares at $5.45/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $100M from 18,348,624 shares at $5.45; net ~$93.5M base, up to ~$107.6M if option exercised.","Funds will support launch readiness, medical affairs, pre-commercialization for CAN-2409 in early localized prostate cancer and phase 3 trial in NSCLC.","Underwriters granted 30-day option to purchase up to 2,752,293 additional shares at same price.","Offering expected to close Feb 23, 2026; Citigroup, Cantor, Stifel are joint bookrunners.","Pro forma cash runway extended into Q1 2028 based on base net proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109728,"accession_number":"0001193125-26-059334","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["1.01","2.02","8.01","7.01","9.01"],"status":"ready","headline":"Candel secures $100M royalty funding from RTW for CAN-2409 prostate cancer launch; prelim cash $119.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Candel enters $100M royalty funding deal with RTW; funds available upon FDA approval of CAN-2409 for localized prostate cancer.","RTW receives 4.67% royalty on US net sales ≤$1B, 1.33% above $1B; cap at $250M; ratchet to 6.67% if sales miss targets.","Preliminary cash and equivalents ~$119.7M as of Dec 31, 2025 (unaudited).","BLA submission for CAN-2409 in localized prostate cancer remains on track for Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126259,"accession_number":"0001193125-25-308719","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Candel Therapeutics hosts virtual R&D Day with pipeline overview","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Virtual R&D Day held December 5, 2025, from 11:00 am to 1:45 pm ET.","Presentation covers viral immunotherapy approach and oncology-focused pipeline.","Presentation available on investor relations website at https://ir.candeltx.com.","No specific clinical data or financial updates disclosed in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126258,"accession_number":"0001193125-25-279072","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Q3 net loss $11.3M; cash $87M; secures $130M debt facility with Trinity Capital","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.3M vs $10.6M in Q3 2024; R&D expenses $8.5M, G&A $4.7M.","Cash and equivalents $87.0M as of Sept 30, 2025; plus $50M upfront from Trinity Capital facility to fund operations into Q1 2027.","Entered $130M term loan with Trinity Capital Inc.; $50M drawn at closing, up to $80M additional subject to milestones.","BLA submission for CAN-2409 in localized prostate cancer planned Q4 2026; phase 3 NSCLC trial to start Q2 2026.","Pausing pancreatic cancer program (PDAC) unless external non-dilutive funding obtained."],"consensus_eps_estimate":-0.1888,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126257,"accession_number":"0001193125-25-238254","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Candel Therapeutics secures $130M loan; reports positive CAN-3110 survival data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $130M term loan facility with Trinity Capital; $50M drawn at closing, up to $80M additional subject to milestones.","Cash and cash equivalents $87.2M as of Sept 30, 2025; loan carries 10.25% initial rate, 36-month interest-only period.","Phase 1b CAN-3110 interim data: median OS 11.8 months (arm A) and 12.0 months (arm B); two patients alive >40 months post-single injection.","Strategic pivot: seek external partnerships for CAN-2409 in PDAC; focus capital on early localized prostate cancer and NSCLC.","Proceeds to initiate phase 3 CAN-2409 trial in NSCLC in Q2 2026 and support BLA submission for prostate cancer planned Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143005,"accession_number":"0000950170-25-110682","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Candel Therapeutics extends office lease through August 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease term extended from August 31, 2026 to August 31, 2029 for 15,197 sq ft in Needham, MA.","Base rent from Sept 2026: $607,880/yr increasing by ~$15,197 annually to $638,274/yr by lease year 10.","No option to extend beyond the Extended Term; premises accepted 'AS-IS' with no landlord improvements.","The amendment updates base rent schedule and landlord address; no other material changes to lease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143004,"accession_number":"0000950170-25-108448","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Q2 net loss $4.8M vs $22.2M loss a year ago; positive phase 3 CAN-2409 results in prostate cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.8M in Q2 2025 vs $22.2M loss in Q2 2024; net other income of $6.4M due to change in warrant liability fair value.","Phase 3 CAN-2409 in localized prostate cancer met primary endpoint with 30% improvement in DFS (HR 0.70, p=0.0155); RMAT designation received.","BLA submission for CAN-2409 in prostate cancer expected in Q4 2026; cash $100.7M sufficient into Q1 2027.","Appointed Charles Schoch as CFO and Maha Radhakrishnan to Board; completed $15M registered direct offering.","Positive overall survival data from phase 2a CAN-2409 in NSCLC (mOS 24.5 months) and pancreatic cancer (mOS 31.4 months)."],"consensus_eps_estimate":-0.1734,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161083,"accession_number":"0001193125-25-145405","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Candel Therapeutics raises $15M via registered direct offering of 3.2M shares at $4.67","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$15M from sale of 3,221,395 shares at $4.67/share; closing expected June 25, 2025.","Purchasers include existing healthcare-focused institutional investors, executive officers, and directors.","Net proceeds to support pre-commercialization and launch readiness for CAN-2409 in prostate cancer; BLA submission planned Q4 2026.","Insider participation signals confidence in Candel's strategy and pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161082,"accession_number":"0001193125-25-144204","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Candel Therapeutics Appoints Charles Schoch as Permanent CFO, Effective June 20, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles Schoch, interim CFO since Jan 2024, promoted to permanent CFO; base salary increased to $440,000, target bonus 40%.","Granted option to purchase 50,000 shares; 25% vests at one year, then ratably over 36 months.","Schoch previously served as VP Finance and Corporate Controller; led capital raise of ~$86M in Q4 2024.","Press release highlights upcoming BLA submission for CAN-2409 in localized prostate cancer.","No family relationships or arrangements with other parties disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161081,"accession_number":"0000950170-25-087696","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Candel shareholders elect three Class I directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Renee Gaeta, Gary J. Nabel, and Joseph C. Papa elected as Class I directors for three-year terms (for/withheld: 13.7M/2.3M, 11.6M/4.4M, 12.8M/3.2M).","Ratification of KPMG as independent auditor for FY2025 passed with 32.2M for, 199K against, 240K abstain.","Broker non-votes on director election totaled 16.7M shares; record date shares outstanding 49.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161080,"accession_number":"0000950170-25-082705","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Candel appoints Maha Radhakrishnan, M.D., to Board; BLA submission for CAN-2409 on track for Q4 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10 directors; Radhakrishnan named to Class II, term expiring 2026.","Appointment effective June 4, 2025; she receives option for 28,480 shares vesting over 3 years.","Radhakrishnan previously Group SVP and Chief Medical Officer at Biogen (Jan 2020 – Mar 2024).","Candel targets Q4 2026 Biologics License Application submission for CAN-2409 in prostate cancer.","She also serves as Executive Partner at Sofinnova Investments since August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161079,"accession_number":"0000950170-25-078079","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants RMAT designation to Candel's CAN-2409 for prostate cancer; phase 3 met endpoint","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["RMAT designation for CAN-2409 (aglatimagene besadenovec) in newly diagnosed localized intermediate-to-high-risk prostate cancer.","Phase 3 trial met primary endpoint: 30% risk reduction in disease-free survival (HR 0.70; p=0.0155) vs placebo.","CAN-2409 improved prostate-specific DFS (38% risk reduction; p=0.0046) and pathological complete response (80.4% vs 63.6%; p=0.0015).","Previously granted Fast Track; BLA submission anticipated by end of 2026 with potential rolling/priority review.","Designation provides intensive FDA guidance to expedite development and review of the therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161078,"accession_number":"0000950170-25-076458","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Candel's CAN-2409 Phase 3 meets primary endpoint (p=0.0155) in localized prostate cancer; ASCO presentation June 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Statistically significant improvement in DFS (p=0.0155) with 30% risk reduction (HR 0.7) for CAN-2409 plus radiotherapy vs placebo plus radiotherapy.","Secondary endpoints met: 80.4% pathological complete response at two-year biopsy vs 63.6% control (p=0.0015); higher PSA nadir <0.2 ng/ml (67.1% vs 58.6%, p=0.0164).","CAN-2409 well tolerated; treatment-related serious adverse events low (1.7% drug arm vs 2.2% control).","Company plans to submit Biologics License Application for CAN-2409 in Q4 2026.","Data to be presented at ASCO 2025 oral abstract session on June 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161077,"accession_number":"0000950170-25-069826","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Therapeutics Q1 net income $7.4M; cash runway into Q1 2027; CAN-2409 BLA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $7.4M in Q1 2025 vs net loss of $8.2M in Q1 2024, driven by warrant liability fair value change.","Cash and equivalents $92.2M as of March 31, 2025; expected to fund operations into Q1 2027.","CAN-2409 phase 3 prostate cancer meets primary endpoint; BLA submission expected Q4 2026.","CAN-2409 in borderline resectable PDAC: mOS 31.4 months vs 12.5 months control in phase 2a.","CAN-2409 in NSCLC (ICI-progressive): mOS 21.5 months vs 9.8–11.8 months standard of care."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161076,"accession_number":"0000950170-25-057398","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Candel Therapeutics announces oral presentation of positive Phase 3 CAN-2409 data in prostate cancer at ASCO 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 CAN-2409 data in localized prostate cancer accepted for oral presentation at ASCO 2025 (May 30-June 3, Chicago).","Presenter is Theodore DeWeese, M.D., Dean and CEO of Johns Hopkins Medicine.","Full abstracts released by ASCO on May 22, 2025 at 5:00 PM ET.","Candel will post presentation details on its website after the event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179275,"accession_number":"0001193125-25-064374","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Candel reports positive final Phase 2a data for CAN-2409 in NSCLC; mOS 24.5 months, long survival tail","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["mOS of 24.5 months in evaluable patients (cohort 1+2, n=46) with advanced NSCLC inadequately responding to ICI.","In patients with progressive disease at baseline (cohort 2, n=41), mOS was 21.5 months, vs. 9.8–11.8 months for docetaxel.","37% (15/41) of progressive disease patients alive >24 months; long tail of survival observed.","In non-squamous NSCLC (n=33), mOS was 25.4 months; ITT analysis showed 16.7 months vs. 9.9–12.3 months for SOC.","Systemic anti-tumor response (abscopal effect) seen in 69% of patients with multiple lesions; safety profile favorable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179274,"accession_number":"0000950170-25-038757","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Therapeutics reports positive phase 3 CAN-2409 data in prostate cancer; cash runway into Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive phase 3 results for CAN-2409 in prostate cancer: 30% risk reduction, 80.4% pathological complete responses; BLA submission expected Q4 2026.","Phase 2a pancreatic cancer: median OS 31.4 months (CAN-2409) vs 12.5 months (control); long-term survivors.","Cash and cash equivalents $102.7M as of Dec 31, 2024; sufficient into Q1 2027.","Net loss for full year 2024: $55.2M; R&D expenses decreased to $19.3M from $24.5M.","Upcoming milestones: NSCLC final OS data Q1 2025; CAN-3110 data Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179273,"accession_number":"0000950170-25-026100","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Candel: CAN-2409 final phase 2 data shows median OS 31.4 mo vs 12.5 mo in pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated median overall survival 31.4 months in CAN-2409 arm vs 12.5 months in control (borderline resectable PDAC).","Three of seven CAN-2409-treated patients still alive at data cut-off (66.0, 63.6, 35.8 months post-enrollment).","Median survival post-progression was 21.2 months with CAN-2409 vs 7.2 months in control arm.","No dose-limiting toxicities or pancreatitis; favorable safety profile.","Company plans to advance CAN-2409 into a larger late-stage randomized trial in PDAC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179272,"accession_number":"0000950170-25-004581","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","7.01","9.01"],"status":"ready","headline":"Candel Therapeutics reports $102.9M cash; updates on CAN-2409 BLA timeline and 2025 milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $102.9M (unaudited) at Dec 31, 2024, vs $35.4M at end-2023; provides runway into Q1 2027.","CAN-2409 BLA submission for prostate cancer on track for Q4 2026; phase 3 data to be presented at upcoming scientific conference.","Updated overall survival data for CAN-2409 in pancreatic and lung cancer expected Q1 2025.","Phase 1b CAN-3110 overall survival data in recurrent high-grade glioma expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195943,"accession_number":"0001193125-24-278717","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Candel prices $80M public offering of common stock and pre-funded warrants at $6.00/share","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Offering: 10,000,001 common shares at $6.00/share plus pre-funded warrants for 3,333,333 shares at $5.99/warrant.","Gross proceeds ~$80M; net proceeds ~$74.7M (or ~$86M if underwriters' 2M-share option is exercised).","Proceeds to fund development, including BLA submission for CAN-2409 in prostate cancer, and general corporate purposes.","Cash runway extended into Q1 2027; key data readouts expected in NSCLC/PDAC (Q1 2025) and recurrent glioblastoma (Q4 2025).","Offering expected to close Dec 16, 2024; joint bookrunners: Citigroup, BofA Securities, Canaccord Genuity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195942,"accession_number":"0001193125-24-274870","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Candel's CAN-2409 meets phase 3 prostate cancer endpoint; BLA submission targeted for Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial met primary endpoint: DFS improvement with HR 0.7 (p=0.0155) vs placebo in intermediate-to-high risk localized prostate cancer.","14.5% relative improvement in DFS at 54 months; 80.4% pathological complete responses at 2-year biopsy vs 63.6% in control (p=0.0015).","Phase 2b trial in low-to-intermediate risk active surveillance patients showed numerical improvement but did not reach statistical significance.","Company intends to initiate FDA discussions and submit Biologics License Application for CAN-2409 in Q4 2026; trial conducted under SPA.","Safety profile consistent with prior studies; most common adverse events were mild-to-moderate flu-like symptoms, fever, and chills."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195941,"accession_number":"0000950170-24-126759","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Therapeutics Q3 net loss $10.6M, cash $16.6M; key prostate cancer data on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.6M in Q3 2024 vs $8.4M in Q3 2023; includes $1.9M other expense from warrant liability.","Cash and cash equivalents $16.6M as of Sept 30, 2024, down from $35.4M at Dec 31, 2023; expects funding to end of Q1 2025.","On track for phase 2b and phase 3 topline data for CAN-2409 in prostate cancer in Q4 2024.","CAN-3110 received FDA orphan drug designation for recurrent high-grade glioma; preclinical melanoma data presented.","R&D expenses $5.4M (down $0.4M YoY); G&A expenses $3.3M (up $0.3M YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195940,"accession_number":"0000950170-24-117578","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Candel reports 3 of 6 rHGG patients alive >1 year after CAN-3110 multiple injections","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b trial of CAN-3110 in recurrent high-grade glioma: 3/6 patients alive at 12.2, 13.0, and 18.7 months post-treatment.","Data show improved survival vs. historical controls; biopsies reveal near absence of tumor cells with dense lymphocyte infiltrates.","Radiologic pseudo-progression observed: post-treatment MRI enhancement despite tumor clearance on histology.","Presented at 2024 IOVC; also disclosed new IL-12/IL-15 multimodal immunotherapy candidate from enLIGHTEN platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212217,"accession_number":"0000950170-24-095775","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Therapeutics Q2 net loss $22.2M; cash runway into Q1 2025; positive CAN-2409 pancreatic data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.2M in Q2 2024 vs $9.6M in Q2 2023; includes $13.7M non-cash warrant liability adjustment.","Cash and cash equivalents $21.5M at June 30, 2024; expects funding operations into Q1 2025.","CAN-2409 in pancreatic cancer: median OS 28.8 months vs 12.5 months control; 24-month survival 71.4% vs 16.7%.","CAN-2409 in NSCLC: median OS 20.6 months in ICI-resistant patients; data presented at ASCO.","Orphan drug designation from FDA for CAN-2409 (pancreatic) and CAN-3110 (rHGG); phase 3 prostate data expected Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231135,"accession_number":"0000950170-24-078795","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Candel Therapeutics stockholders elect three Class III directors and ratify KPMG as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nicoletta Loggia (7.18M for), Christopher Martell (6.99M for), Diem Nguyen (7.02M for) elected as Class III directors.","KPMG LLP ratified as independent auditor for fiscal 2024 with 14.62M for, 98.9K against, 42.9K abstain.","Meeting held June 26, 2024; record date May 15, 2024; 29.76M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231134,"accession_number":"0000950170-24-066608","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Candel Therapeutics reduces stockholder meeting quorum threshold to one-third","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to bylaws, effective May 29, 2024.","Quorum requirement lowered from majority to one-third of shares entitled to vote.","Amendment applies to all stockholder meetings of Candel Therapeutics, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231133,"accession_number":"0000950170-24-064022","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Candel reports Phase 2 CAN-2409 data: 20.6-month median OS in NSCLC patients with ICI resistance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival of 20.6 months in NSCLC patients with progressive disease despite ICI, vs 11.6 months historical SoC docetaxel.","mOS of 22.0 months across all 46 patients with inadequate ICI response.","71.4% of evaluable metastatic patients had beneficial effect on both injected and uninjected tumors (abscopal response).","Increased circulating CD8+ and CD4+ memory T cells after second injection correlated with prolonged survival.","Favorable safety: no grade 4+ TRAEs; three grade 3 events (1 pyrexia, 2 pneumonitis)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231132,"accession_number":"0000950170-24-059109","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Therapeutics Q1 net loss $8.2M; highlights positive CAN-2409 pancreatic cancer survival data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.2M vs $8.8M YoY; R&D expenses $4.1M, G&A $3.8M.","Cash $25.7M as of March 31, 2024; expected to fund operations into Q4 2024.","CAN-2409 pancreas phase 2: median OS 28.8 months vs 12.5 months control; 24-month survival 71.4% vs 16.7%.","Phase 2 CAN-2409 NSCLC topline OS data to be presented at ASCO on June 3, 2024.","Phase 3 CAN-2409 prostate cancer disease-free survival data expected in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231131,"accession_number":"0000950170-24-047941","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Candel to present CAN-3110 glioma data and CAN-2409 NSCLC topline OS at ASCO 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two abstracts accepted for ASCO 2024: CAN-3110 phase 1 (recurrent high-grade glioma, cohort C) and CAN-2409 phase 2 (NSCLC with inadequate ICI response).","CAN-3110 data: multiple injections (up to six) feasible and well tolerated in cohort C.","CAN-2409 presentation will show topline overall survival data with valacyclovir + continued ICI.","Presentations on June 1 (CAN-3110) and June 3 (CAN-2409) at ASCO in Chicago.","Full abstracts released by ASCO on May 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231130,"accession_number":"0000950170-24-043532","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Candel Therapeutics receives FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Orphan Drug Designation for CAN-2409 (multimodal immunotherapy) in pancreatic cancer.","Fast Track Designation also previously granted; both designations support development.","Phase 2 data showed median OS 28.8 mo (CAN-2409+SoC) vs 12.5 mo (SoC alone); 24-mo survival 71.4% vs 16.7%.","No new safety signals; CAN-2409 generally well tolerated with no pancreatitis or DLTs.","Orphan Drug status provides tax credits, fee waivers, and 7-year market exclusivity if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231129,"accession_number":"0000950170-24-042800","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Candel presents second enLIGHTEN candidate at AACR; induces TLS, enhances anti-PD-1 in mice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second multimodal immunotherapy candidate from enLIGHTEN platform targets tertiary lymphoid structures (TLS) in solid tumors.","Two payload combinations, predicted via enLIGHTEN analytics, induced TLS, monotherapy anti-tumor activity, and boosted anti-PD-1 response in mouse models.","Milestone accelerated from Q3 2024 to April 2024, validating platform speed.","TLS induction is a novel strategy to improve anti-tumor immunity; data presented at AACR April 5-10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231128,"accession_number":"0000950170-24-041619","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Candel reports CAN-2409 phase 2 interim data: median OS 28.8 vs 12.5 months in pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated median overall survival 28.8 months for CAN-2409 group vs 12.5 months for control in borderline resectable PDAC.","24-month survival rate 71.4% for CAN-2409 vs 16.7% control; 36-month rate 47.6% vs 16.7%.","4 of 7 CAN-2409 patients alive at data cut-off (2 >50 months); only 1 of 6 control alive.","Immune activation confirmed: dense CD8+ TILs, dendritic cells, B cells in tumor; increased granzymes and IFN-γ in blood.","No dose-limiting toxicities or pancreatitis; FDA Fast Track Designation granted in December 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249514,"accession_number":"0000950170-24-037624","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel reports Q4 2023 net loss $11.1M; cash $35.4M; Phase 3 prostate data on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $11.1M vs $5.1M Q4 2022; full year net loss $37.9M vs $18.8M.","Cash and equivalents $35.4M at Dec 31, 2023 ($70.1M end 2022); expects runway into Q4 2024.","R&D expenses $7.3M Q4 2023 ($5.0M Q4 2022) and $24.5M full year ($20.8M 2022).","FDA Fast Track Designations: CAN-2409 for NSCLC and pancreatic cancer, CAN-3110 for recurrent HGG.","Anticipated milestones: Phase 2 NSCLC data Q2 2024; Phase 3 prostate topline data Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249513,"accession_number":"0000950170-24-026877","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Candel accelerates unveiling of second enLIGHTEN candidate to AACR April 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second enLIGHTEN platform candidate to be presented at AACR April 9, 2024; originally planned for Q3 2024.","First-in-class multimodal immunotherapy designed to induce tertiary lymphoid structures for solid tumors.","Abstract LB263; poster session on Tuesday April 9, 9:00 AM - 12:30 PM PT in San Diego.","Candidate follows Alpha 201-macro-1; data from preclinical models shown at SITC 2023 and Oncolytic Virus Conference 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249512,"accession_number":"0000950170-24-014191","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Candel receives FDA Fast Track Designation for CAN-3110 in recurrent high-grade glioma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation for CAN-3110, an HSV-1 oncolytic viral immunotherapy for recurrent HGG to improve overall survival.","Phase 1b data published in Nature (Oct 2023) showed median overall survival ~12 months after single injection vs historical <6-9 months.","Positive HSV-1 serology associated with mOS of 14 months; T-cell repertoire expansion and local/systemic antitumoral response observed.","Ongoing phase 1b trial evaluating multiple injections of CAN-3110; additional data expected in H2 2024.","Fast Track designation may accelerate development and regulatory review for this therapy-resistant brain cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249511,"accession_number":"0000950170-24-004262","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Candel Therapeutics CFO Jason Amello resigns; Charles Schoch named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason A. Amello resigned as CFO effective Jan 12, 2024, to pursue another opportunity.","Board appointed Charles Schoch as interim CFO, effective Jan 12, 2024.","Schoch had served as VP of Finance and Corporate Controller since March 2023.","Schoch's annual base salary increased to $325,000 as interim CFO.","Schoch is a CPA with prior experience at Corbus Pharmaceuticals and PwC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249510,"accession_number":"0000950170-24-000539","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Candel Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Dec 28, 2023 that bid price compliance is regained.","Previously warned on Nov 15, 2023 for closing below $1.00 for 30 consecutive days.","Nasdaq has closed the matter; no further action required.","Company's common stock (CADL) continues trading on Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266974,"accession_number":"0000950170-23-070509","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Candel Therapeutics CFO Jason Amello resigns; Charles Schoch appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Amello resigned as CFO, principal financial and accounting officer, effective January 12, 2024, to pursue another opportunity.","Resignation not due to any disagreement with auditors or company on operations, policies, or financial disclosures.","Charles Schoch, VP of Finance and Corporate Controller, will serve as Interim CFO while a permanent replacement is sought.","Amello will remain as an advisor to support transition of responsibilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266973,"accession_number":"0000950170-23-069533","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA grants Fast Track Designation to Candel's CAN-2409 for pancreatic cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track Designation for CAN-2409 (adenovirus immunotherapy) plus valacyclovir in pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.","Phase 2 interim data (Nov 2023): 71.4% estimated survival at 24 and 36 months with CAN-2409 + SoC vs 16.7% for SoC alone in borderline resectable PDAC.","Updated overall survival data from interim analysis expected Q2 2024.","CAN-2409 shown to activate immunologic antitumoral response in 'cold' tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266972,"accession_number":"0000950170-23-066248","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Candel Therapeutics announces 50% workforce reduction, restructuring to focus on CAN-3110 and enLIGHTEN platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately 50% workforce reduction; one-time restructuring charge of ~$0.7M in Q4 2023.","Cash runway extended into Q4 2024; company prioritizes CAN-3110 development and enLIGHTEN platform.","Key CAN-2409 readouts in 2024: NSCLC overall survival (Q2), pancreatic interim (Q2), prostate (Q4).","Company will explore partnering opportunities for CAN-2409 to reduce commercial manufacturing costs.","Initial CAN-3110 repeated injection data in recurrent high-grade glioma expected H2 2024; new enLIGHTEN data Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266971,"accession_number":"0000950170-23-065567","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2023-11-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Candel Therapeutics receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified CADL that bid price below $1.00 for 30 consecutive business days.","Company has 180 days, until May 13, 2024, to regain compliance.","Compliance requires closing bid price at $1.00 or more for 10 consecutive business days.","If not compliant, may qualify for second 180-day period by transferring to Nasdaq Capital Market.","Common stock continues trading on Nasdaq Global Market under CADL; no immediate effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266970,"accession_number":"0000950170-23-061558","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Therapeutics Q3 2023 net loss $8.4M; cash runway into Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.4M in Q3 2023, versus $8.7M loss in Q3 2022; no revenue recognized.","Cash and equivalents $43.0M as of Sept 30, 2023; expected to fund operations into Q2 2024.","R&D expenses $5.8M (+7.4% YoY) driven by CAN-2409 manufacturing and regulatory work.","G&A expenses $3.0M (-14.3% YoY) due to lower professional service and consulting costs.","Topline overall survival data for CAN-2409 in NSCLC expected Q2 2024; prostate cancer data in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266969,"accession_number":"0000950170-23-059042","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Candel presents preclinical data at SITC for enLIGHTEN platform; Alpha-201-macro1 shows enhanced cancer cell killing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical data for enLIGHTEN Discovery Platform presented at SITC 2023 Annual Meeting in San Diego.","Alpha-201-macro1, first experimental agent from platform, targets CD47/SIRPα pathway via local delivery.","enLIGHTEN Advanced Analytics suite predicted multi-gene payload combinations from ICI-treated patient datasets.","Viral chassis Alpha-201 armed with immunostimulatory payloads enhanced PBMC-mediated cancer cell killing in preclinical models.","Data validate in silico prediction of payload combinations using human datasets to de-risk viral immunotherapy development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266968,"accession_number":"0000950170-23-059024","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Candel reports CAN-2409 phase 2 interim data: 71.4% survival at 36 months vs 16.7% in borderline PDAC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated overall survival rate 71.4% at 24 & 36 months for CAN-2409 arm vs 16.7% control in borderline resectable PDAC.","Median overall survival not yet reached in CAN-2409 arm; control arm median OS was 12.5 months.","Robust immune activation: dense aggregates of CD8+ granzyme B+ T cells, dendritic cells, and B cells in tumor.","No dose-limiting toxicities or pancreatitis reported; multiple injections generally well tolerated.","5 of 7 CAN-2409 patients alive at data cutoff; two survived >45 months. Control: 1 of 6 alive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266967,"accession_number":"0000950170-23-053894","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Candel announces Nature publication: CAN-3110 extends survival in recurrent high-grade glioma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial (n=41) of CAN-3110 in recurrent HGG showed median OS of 11.6 months, nearly double historical 6-9 months.","HSV-1 seropositive patients had median OS 14.2 months vs 7.8 months for seronegative; seroconversion linked to improved survival.","Treatment well tolerated with no dose-limiting toxicity; increased immune cell infiltration and T-cell repertoire diversity observed.","Arm C will evaluate up to six injections of CAN-3110, supported by Break Through Cancer foundation.","Publication in Nature titled 'Clinical trial links oncolytic immunoactivation to survival in glioblastoma'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":601915042.0099379,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-10-18T23:59:59+00:00|266967"}